Bin Zhao
Merck & Co., Inc., Rahway, NJ, USA (United States) · 106 works · 3,845 citations · h-index 22
Top works
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
- Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
- Macropinocytosis Is the Endocytic Pathway That Mediates Macrophage Foam Cell Formation with Native Low Density Lipoprotein
- Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC
- Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407
- Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
- Exploiting innate immunity for cancer immunotherapy
- Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
- Redistribution of macrophage cholesteryl ester hydrolase from cytoplasm to lipid droplets upon lipid loading
- Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy
- Risk factors and outcomes of hospitalized patients with blood infections caused by multidrug-resistant Acinetobacter baumannii complex in a hospital of Northern China
- Effects of poly(l-lysine)-modified Fe3O4 nanoparticles on endogenous reactive oxygen species in cancer stem cells
- Autophagy-based survival prognosis in human colorectal carcinoma
- Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real‐world pharmacoepidemiology study of post‐marketing surveillance data
- Vitiligo associated with type 2 immune inhibitors: FAERS analysis and literature review
- Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices
- CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity
- Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials
- Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407
- Risk of fatal adverse events in cancer patients treated with sunitinib